Quantcast

AbbVie to Buy Botox-Maker Allergan, Look Ahead to G-20


Shutterstock photo

Tuesday, June 25, 2019

For the second consecutive day, we see another major acquisition during the pre-market period. Yesterday was the Gaming industry's buyout of Caesars Entertainment CZR by Eldorado Resorts ERI , and today we turn to biopharma: AbbVie ABBV has agreed to purchase Botox maker Allergan AGN for roughly $63 billion in cash and stock.

The deal reportedly values Allergan at a 45% premium to Monday's closing price. Thus far, since the deal has been announced, shares of Allergan have blossomed 32%. AbbVie, on a quest to replace coming lost revenues on Humira's generic competition, have dipped around 7.5% thus far ahead of the opening bell.

Allergan has been a targeted acquisition for the past several years - back in 2015, Pfizer PFE , which recently acquired Array Biopharma ARRY , was prepared to pay almost double this morning's headline price for Allergan. AbbVie, which spun off from Abbott Labs ABT 6 years ago, had been rated a Zacks Rank #2 (Buy) ahead of the announced transaction; Allergan was carrying a Zacks Rank #3 (Hold).

Trump-Xi to Meet This Weekend

As the leaders of the world's top economies join together for the G-20 summit in Osaka, Japan at the end of this week, President Trump and Xi have scheduled a separate, private meeting between the embattled two leaders. The ongoing trade war, having been put into effect as of fall last year, has shown little progress over the last month, when talks nearing a deal fell apart.

U.S. Commerce Secretary Wilbur Ross does not want investors to get their hopes up that a trade deal is coming soon, certainly not as a direct result of this Saturday's scheduled meeting between Trump and Xi. What investors might more reasonably expect in the near term is a pause in tariffs and a resuming of talks between the two sides over the summer.

At the G-20 summit last year in Argentina, Trump and Xi also met privately. Routinely, reports from inside these private talks are very positive, but now a year on with no trade agreement in sight, investors have understandably tempered their expectations.

Mark Vickery
Senior Editor

Questions or comments about this article and/or its author? Click here>>

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Caesars Entertainment Corporation (CZR): Free Stock Analysis Report

Pfizer Inc. (PFE): Free Stock Analysis Report

Allergan plc (AGN): Free Stock Analysis Report

AbbVie Inc. (ABBV): Free Stock Analysis Report

Abbott Laboratories (ABT): Free Stock Analysis Report

Eldorado Resorts, Inc. (ERI): Free Stock Analysis Report

Array BioPharma Inc. (ARRY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.





This article appears in: Investing , US Markets , Stocks
Referenced Symbols: CZR , PFE , AGN , ABBV , ABT



More from Zacks.com

Subscribe







Zacks.com
Contributor:

Zacks.com

Equity Research












Research Brokers before you trade

Want to trade FX?